Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of ASN51 in Adults With Early Alzheimer's Disease
NCT06677203 is registered in ClinicalTrials.gov with Asceneuron S.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of ASN51 in Adults With Early Alzheimer's Disease
- Lead sponsor
- Asceneuron S.A.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- October 16, 2024
- Completion date
- November 8, 2024
- Enrollment
- 123 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.